Physician profile
Steven E Parnell
NPI 1124002761
$1,613.52
in general payments reported to CMS, 2019-2025
44 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $309 · 2021: $285 · 2022: $275 · 2023: $271 · 2024: $141 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.69 | 2020-2025 | Repatha, Otezla, Prolia |
| Grifols USA, LLC | $80.97 | 2019-2023 | Prolastin-C Liquid |
| Novo Nordisk INC | $80.06 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $72.57 | 2020-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $64.86 | 2021-2023 | Austedo |
| Kowa Pharmaceuticals America, INC. | $63.06 | 2020-2021 | |
| Abbvie INC. | $59.71 | 2022-2025 | |
| Organogenesis INC. | $57.35 | 2022-2024 | |
| Horizon Therapeutics Plc | $53.74 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.21 | 2019-2022 | |
| Corium, LLC | $51.91 | 2022-2023 | Adlarity |
| Xeris Pharmaceuticals, INC. | $51.62 | 2021-2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $49.18 | 2020-2021 | |
| Romark Laboratories, Lc | $46.90 | 2019-2020 | |
| Hologic Sales and Service, LLC | $46.71 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Parnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.